Hikma Pharmaceuticals Public annual debt-to-assets ratio
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Debt-to-Assets Ratio Growth & History (HIK)
Hikma Pharmaceuticals Public's debt-to-assets ratio was 0.28 for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual debt-to-assets ratio history
| Fiscal year | Period ended | Debt-to-assets ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.28 | 0.03 | +11.17% |
| 2024 | 2024-12-31 | 0.25 | −0.00 | −0.02% |
| 2023 | 2023-12-31 | 0.25 | −0.03 | −11.32% |
| 2022 | 2022-12-31 | 0.29 | 0.09 | +48.30% |
| 2021 | 2021-12-31 | 0.19 | −0.03 | −14.15% |
| 2020 | 2020-12-31 | 0.23 | — | — |
Hikma Pharmaceuticals Public quarterly debt-to-assets ratio
Q4.24
Q2.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Debt-to-assets ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.34 | 0.06 | +19.66% |
| Q4 2025 | 2025-12-31 | 0.28 | 0.03 | +11.17% |
| Q2 2025 | 2025-06-30 | 0.28 | — | — |
| Q4 2024 | 2024-12-31 | 0.25 | — | — |
Hikma Pharmaceuticals Public debt-to-assets ratio trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's debt-to-assets ratio increased from 0.23 to 0.28, a change of 0.06. The latest reported quarter, Q2 2026, shows 0.34.
About the metric
What the debt-to-assets ratio means
The debt-to-assets ratio shows the portion of a company’s reported assets financed with interest-bearing debt. It is a leverage measure and should not be confused with total liabilities divided by assets.
Calculation and source
How debt-to-assets is calculated
TickerStat calculates debt-to-assets as total interest-bearing debt divided by total assets at the same reporting-period end. Periods with missing debt or non-positive assets are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...